<DOC>
	<DOC>NCT01147458</DOC>
	<brief_summary>PF-04191834 works in animal models by inhibiting one of the enzymes, 5-lipoxygenasein which is involved in the pathway that causes inflammation and pain. The purpose of this study is to test how effective, safe and tolerated PF-04191834 is in patients with osteoarthritis of the knee by itself or with naproxen, particularly to test if patients have less pain.</brief_summary>
	<brief_title>A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee</brief_title>
	<detailed_description>This study has been terminated in response to a reported serious adverse event (SAE). The sponsor's assessment of the limited data available at the time of the initial SAE report was that the SAE may alter the potential benefit - risk profile of the study medication.</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Subjects must have a diagnosis of osteoarthritis based on the American College of Rheumatology criteria confirmed by an Xray Subjects must be willing and able to stop all current pain therapy for the duration of the study Subjects must be willing and able to complete a daily diary BMI of &gt;39 kg/m2 Known allergy or hypersensitivity to naproxen Any condition or medical history that might interfere with the subject's ability to complete the study visits and assessments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Cross-over</keyword>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>tolerability</keyword>
	<keyword>osteoarthritis</keyword>
	<keyword>knee</keyword>
	<keyword>pain</keyword>
</DOC>